Reconnect Labs, a Swiss-based clinical-stage pharmaceutical company, is pioneering the development of Regenerative Therapeutics™ aimed at mental health, leveraging cutting-edge neuroscience and precision psychopharmacology.
Founded by neuroscientists affiliated with the University of Zurich Psychiatric University Clinic, the company focuses on overcoming the challenges associated with first-generation psychoplastogens, creating a portfolio targeting affective and neurodegenerative disorders, chronic pain, and insomnia.
As a University of Zurich spin-off, Reconnect Labs is dedicated to advancing next-generation psychedelic medicines that promise greater safety, tolerability, and effectiveness for mental health, driven by a commitment to ethical standards and patient-centred care.
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates